Agomelatine versus paroxetine in treating depressive and anxiety symptoms in patients with chronic kidney disease

Jian-wei Chen, Shu-qin Xie Department of Nephrology, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China Objective: Depressive and anxiety symptoms could affect the quality of life and prognostic outcomes in chronic kidney disease (CKD) patients, but only a few studies...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chen JW, Xie SQ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	chronic kidney disease CKD paroxetine agomelatine Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/2f923fd7c80f45358b16c470412526a7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2f923fd7c80f45358b16c470412526a7
record_format	dspace
spelling	oai:doaj.org-article:2f923fd7c80f45358b16c470412526a72021-12-02T07:22:44ZAgomelatine versus paroxetine in treating depressive and anxiety symptoms in patients with chronic kidney disease1178-2021https://doaj.org/article/2f923fd7c80f45358b16c470412526a72018-02-01T00:00:00Zhttps://www.dovepress.com/agomelatine-versus-paroxetine-in-treating-depressive-and-anxiety-sympt-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Jian-wei Chen, Shu-qin Xie Department of Nephrology, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China Objective: Depressive and anxiety symptoms could affect the quality of life and prognostic outcomes in chronic kidney disease (CKD) patients, but only a few studies focus on the interventions to manage or prevent these symptoms in CKD patients. Therefore, this study was conducted to compare the efficacy and acceptability of agomelatine versus paroxetine in treating depressive and anxiety symptoms in CKD patients. Methods: CKD stage 2–4 patients with depressive and anxiety symptoms were included. The first patient was randomized in April 2013 and the last clinic visit occurred in March 2017. The included patients were randomly assigned to receive paroxetine 20–40 mg/day or agomelatine 25–50 mg/day. The treatment was continued for 12 weeks. The Hamilton Depression Rating Scale (HDRS) (17-item) and Hamilton Anxiety Rating Scale (HARS) were the primary outcome measures, and the response rate, remission rate, and Activities of Daily Living (ADL) scale were the secondary outcome measures. Meanwhile, the adverse events were recorded during the whole treatment period. Results: At baseline and week 4, both groups had similar average HDRS and HARS scores. But at week 8 and 12, compared to the patients receiving paroxetine, the patients receiving agomelatine had significantly lower average HDRS scores (p=0.002, p=0.001, respectively) and HARS scores (p<0.00001, p<0.00001, respectively). At week 12, the patients receiving agomelatine had a non-significantly lower average ADL score, and non-significantly higher response and remission rates. The adverse events in both groups were mild and transient. Conclusion: These results demonstrated that the agomelatine had some advantages over paroxetine in treating CKD stage 2–4 patients with depressive and anxiety symptoms, and future studies are needed to further explore its efficacy and acceptability. Keywords: chronic kidney disease, CKD, paroxetine, agomelatineChen JWXie SQDove Medical Pressarticlechronic kidney diseaseCKDparoxetineagomelatineNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 14, Pp 547-552 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	chronic kidney disease CKD paroxetine agomelatine Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	chronic kidney disease CKD paroxetine agomelatine Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Chen JW Xie SQ Agomelatine versus paroxetine in treating depressive and anxiety symptoms in patients with chronic kidney disease
description	Jian-wei Chen, Shu-qin Xie Department of Nephrology, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China Objective: Depressive and anxiety symptoms could affect the quality of life and prognostic outcomes in chronic kidney disease (CKD) patients, but only a few studies focus on the interventions to manage or prevent these symptoms in CKD patients. Therefore, this study was conducted to compare the efficacy and acceptability of agomelatine versus paroxetine in treating depressive and anxiety symptoms in CKD patients. Methods: CKD stage 2–4 patients with depressive and anxiety symptoms were included. The first patient was randomized in April 2013 and the last clinic visit occurred in March 2017. The included patients were randomly assigned to receive paroxetine 20–40 mg/day or agomelatine 25–50 mg/day. The treatment was continued for 12 weeks. The Hamilton Depression Rating Scale (HDRS) (17-item) and Hamilton Anxiety Rating Scale (HARS) were the primary outcome measures, and the response rate, remission rate, and Activities of Daily Living (ADL) scale were the secondary outcome measures. Meanwhile, the adverse events were recorded during the whole treatment period. Results: At baseline and week 4, both groups had similar average HDRS and HARS scores. But at week 8 and 12, compared to the patients receiving paroxetine, the patients receiving agomelatine had significantly lower average HDRS scores (p=0.002, p=0.001, respectively) and HARS scores (p<0.00001, p<0.00001, respectively). At week 12, the patients receiving agomelatine had a non-significantly lower average ADL score, and non-significantly higher response and remission rates. The adverse events in both groups were mild and transient. Conclusion: These results demonstrated that the agomelatine had some advantages over paroxetine in treating CKD stage 2–4 patients with depressive and anxiety symptoms, and future studies are needed to further explore its efficacy and acceptability. Keywords: chronic kidney disease, CKD, paroxetine, agomelatine
format	article
author	Chen JW Xie SQ
author_facet	Chen JW Xie SQ
author_sort	Chen JW
title	Agomelatine versus paroxetine in treating depressive and anxiety symptoms in patients with chronic kidney disease
title_short	Agomelatine versus paroxetine in treating depressive and anxiety symptoms in patients with chronic kidney disease
title_full	Agomelatine versus paroxetine in treating depressive and anxiety symptoms in patients with chronic kidney disease
title_fullStr	Agomelatine versus paroxetine in treating depressive and anxiety symptoms in patients with chronic kidney disease
title_full_unstemmed	Agomelatine versus paroxetine in treating depressive and anxiety symptoms in patients with chronic kidney disease
title_sort	agomelatine versus paroxetine in treating depressive and anxiety symptoms in patients with chronic kidney disease
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/2f923fd7c80f45358b16c470412526a7
work_keys_str_mv	AT chenjw agomelatineversusparoxetineintreatingdepressiveandanxietysymptomsinpatientswithchronickidneydisease AT xiesq agomelatineversusparoxetineintreatingdepressiveandanxietysymptomsinpatientswithchronickidneydisease
_version_	1718399448428576768

Agomelatine versus paroxetine in treating depressive and anxiety symptoms in patients with chronic kidney disease

Ejemplares similares